Amisulpride versus other atypical antipsychotics for schizophrenia
Background In many countries of the industrialised world second generation (atypical) antipsychotics have become first line drug treatments for people with schizophrenia. The question as to whether, and if so how much, the effects of the various second generation antipsychotics differ is a matter of...
Gespeichert in:
| Veröffentlicht in: | Cochrane database of systematic reviews 2010-01, Vol.2013 (2), p.CD006624-CD006624 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | CD006624 |
|---|---|
| container_issue | 2 |
| container_start_page | CD006624 |
| container_title | Cochrane database of systematic reviews |
| container_volume | 2013 |
| creator | Komossa, Katja Rummel‐Kluge, Christine Hunger, Heike Schmid, Franziska Schwarz, Sandra Silveira da Mota Neto, Joaquim I Kissling, Werner Leucht, Stefan Komossa, Katja |
| description | Background
In many countries of the industrialised world second generation (atypical) antipsychotics have become first line drug treatments for people with schizophrenia. The question as to whether, and if so how much, the effects of the various second generation antipsychotics differ is a matter of debate. In this review we examine how the efficacy and tolerability of amisulpride differs from that of other second generation antipsychotics.
Objectives
To evaluate the effects of amisulpride compared with other atypical antipsychotics for people with schizophrenia and schizophrenia‐like psychoses.
Search methods
We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CINAHL, EMBASE, MEDLINE and PsycINFO.
We updated this search in July 2012 and added 47 new trials to the awaiting classification section.
Selection criteria
We included randomised, at least single‐blind, trials comparing oral amisulpride with oral forms of aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia‐like psychoses.
Data collection and analysis
We extracted data independently. For continuous data we calculated weighted mean differences (MD), for dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention‐to‐treat basis based on a random effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate.
Main results
The review currently includes ten short to medium term trials with 1549 participants on three comparisons: amisulpride versus olanzapine, risperidone and ziprasidone. The overall attrition rate was considerable (34.7%) with no significant difference between groups. Amisulpride was similarly effective as olanzapine and risperidone and more effective than ziprasidone (leaving the study early due to inefficacy: n=123, 1 RCT, RR 0.21 CI 0.05 to 0.94, NNT 8 CI 5 to 50). Amisulpride induced less weight gain than risperidone (n=585, 3 RCTs, MD ‐0.99 CI ‐1.61 to ‐0.37) or olanzapine (n=671, 3 RCTs, MD ‐2.11 CI ‐2.94 to ‐1.29). Olanzapine was also associated with a higher increase of glucose (n=406, 2 RCTs, MD ‐7.30 CI ‐7.62 to ‐6.99). There was no difference in terms of cardiac effects and extra pyramidal symptoms (EPS) compared with olanzapine (akathisia: n= 587, 2 RCTs, RR 0.66 CI 0.36 to 1.21), compared with risperidone (akathisia: n=586, 3 RCTs, RR 0.80 CI 0.58 t |
| doi_str_mv | 10.1002/14651858.CD006624.pub2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4164462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733611867</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5252-6be7c9029a86013ec37a6a35174a4937a2ff1e2ab5ea2d3f0116a4fc3b7d75613</originalsourceid><addsrcrecordid>eNqFkMtOwzAURC0EoqXwC1V2rFL8TrJBastTqsQG1pbjOMQojYOdFIWvJ1EfKmxY2daM59w7AEwRnCEI8Q2inKGYxbPlHYScYzqr2xSfgPEghINyenQfgQvvPyAkPMHRORhhCBPEkmQMFvO18W1ZO5PpYKOdb31gm0K7QDZdbZQsA1k1pvadKmxjlA9y6wKvCvNt68LpyshLcJbL0uur3TkBbw_3r8uncPXy-Lycr0LFMMMhT3WkEogTGXOIiFYkklwShiIqadI_cJ4jjWXKtMQZySFCXNJckTTKIsYRmYDbbW6_6VpnSleNk6XoR19L1wkrjfitVKYQ73YjKOKUctwHXO8CnP1stW9Ev7vSZSkrbVsvIkI4QjGPeiffOpWz3judHygIiqF_se9f7Psf2ANiejzj4du-8N6w2Bq-TKk7oawqXI__J_cP5Qcz1pfL</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733611867</pqid></control><display><type>article</type><title>Amisulpride versus other atypical antipsychotics for schizophrenia</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Komossa, Katja ; Rummel‐Kluge, Christine ; Hunger, Heike ; Schmid, Franziska ; Schwarz, Sandra ; Silveira da Mota Neto, Joaquim I ; Kissling, Werner ; Leucht, Stefan ; Komossa, Katja</creator><creatorcontrib>Komossa, Katja ; Rummel‐Kluge, Christine ; Hunger, Heike ; Schmid, Franziska ; Schwarz, Sandra ; Silveira da Mota Neto, Joaquim I ; Kissling, Werner ; Leucht, Stefan ; Komossa, Katja</creatorcontrib><description>Background
In many countries of the industrialised world second generation (atypical) antipsychotics have become first line drug treatments for people with schizophrenia. The question as to whether, and if so how much, the effects of the various second generation antipsychotics differ is a matter of debate. In this review we examine how the efficacy and tolerability of amisulpride differs from that of other second generation antipsychotics.
Objectives
To evaluate the effects of amisulpride compared with other atypical antipsychotics for people with schizophrenia and schizophrenia‐like psychoses.
Search methods
We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CINAHL, EMBASE, MEDLINE and PsycINFO.
We updated this search in July 2012 and added 47 new trials to the awaiting classification section.
Selection criteria
We included randomised, at least single‐blind, trials comparing oral amisulpride with oral forms of aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia‐like psychoses.
Data collection and analysis
We extracted data independently. For continuous data we calculated weighted mean differences (MD), for dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention‐to‐treat basis based on a random effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate.
Main results
The review currently includes ten short to medium term trials with 1549 participants on three comparisons: amisulpride versus olanzapine, risperidone and ziprasidone. The overall attrition rate was considerable (34.7%) with no significant difference between groups. Amisulpride was similarly effective as olanzapine and risperidone and more effective than ziprasidone (leaving the study early due to inefficacy: n=123, 1 RCT, RR 0.21 CI 0.05 to 0.94, NNT 8 CI 5 to 50). Amisulpride induced less weight gain than risperidone (n=585, 3 RCTs, MD ‐0.99 CI ‐1.61 to ‐0.37) or olanzapine (n=671, 3 RCTs, MD ‐2.11 CI ‐2.94 to ‐1.29). Olanzapine was also associated with a higher increase of glucose (n=406, 2 RCTs, MD ‐7.30 CI ‐7.62 to ‐6.99). There was no difference in terms of cardiac effects and extra pyramidal symptoms (EPS) compared with olanzapine (akathisia: n= 587, 2 RCTs, RR 0.66 CI 0.36 to 1.21), compared with risperidone (akathisia: n=586, 3 RCTs, RR 0.80 CI 0.58 to 1.11) and compared with ziprasidone (akathisia: n=123, 1 RCT, RR 0.63, CI 0.11 to 3.67).
Authors' conclusions
There is little randomised evidence comparing amisulpride with other second generation antipsychotic drugs. We could only find trials comparing amisulpride with olanzapine, risperidone and ziprasidone. We found amisulpride may be somewhat more effective than ziprasidone, and more tolerable in terms of weight gain and other associated problems than olanzapine and risperidone. These data, however, are based on only ten short to medium term studies and therefore too limited to allow for firm conclusions.
Note: the 47 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.</description><identifier>ISSN: 1465-1858</identifier><identifier>ISSN: 1469-493X</identifier><identifier>EISSN: 1465-1858</identifier><identifier>EISSN: 1469-493X</identifier><identifier>DOI: 10.1002/14651858.CD006624.pub2</identifier><identifier>PMID: 20091599</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Amisulpiride ; Amisulpride ; Antipsychotic Agents ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - therapeutic use ; Antipsychotic medication: atypical ; Anti‐psychotics ; Benzodiazepines ; Benzodiazepines - adverse effects ; Benzodiazepines - therapeutic use ; Clinical care ‐ by treatment category ; Drugs ; Humans ; Medicine General & Introductory Medical Sciences ; Mental health ; Olanzapine ; Piperazines ; Piperazines - adverse effects ; Piperazines - therapeutic use ; Randomized Controlled Trials as Topic ; Risperidone ; Risperidone - adverse effects ; Risperidone - therapeutic use ; Schizophrenia ; Schizophrenia & psychosis ; Schizophrenia - drug therapy ; Sulpiride ; Sulpiride - adverse effects ; Sulpiride - analogs & derivatives ; Sulpiride - therapeutic use ; Thiazoles ; Thiazoles - adverse effects ; Thiazoles - therapeutic use</subject><ispartof>Cochrane database of systematic reviews, 2010-01, Vol.2013 (2), p.CD006624-CD006624</ispartof><rights>Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.</rights><rights>Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5252-6be7c9029a86013ec37a6a35174a4937a2ff1e2ab5ea2d3f0116a4fc3b7d75613</citedby><cites>FETCH-LOGICAL-c5252-6be7c9029a86013ec37a6a35174a4937a2ff1e2ab5ea2d3f0116a4fc3b7d75613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20091599$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Komossa, Katja</creatorcontrib><creatorcontrib>Rummel‐Kluge, Christine</creatorcontrib><creatorcontrib>Hunger, Heike</creatorcontrib><creatorcontrib>Schmid, Franziska</creatorcontrib><creatorcontrib>Schwarz, Sandra</creatorcontrib><creatorcontrib>Silveira da Mota Neto, Joaquim I</creatorcontrib><creatorcontrib>Kissling, Werner</creatorcontrib><creatorcontrib>Leucht, Stefan</creatorcontrib><creatorcontrib>Komossa, Katja</creatorcontrib><title>Amisulpride versus other atypical antipsychotics for schizophrenia</title><title>Cochrane database of systematic reviews</title><addtitle>Cochrane Database Syst Rev</addtitle><description>Background
In many countries of the industrialised world second generation (atypical) antipsychotics have become first line drug treatments for people with schizophrenia. The question as to whether, and if so how much, the effects of the various second generation antipsychotics differ is a matter of debate. In this review we examine how the efficacy and tolerability of amisulpride differs from that of other second generation antipsychotics.
Objectives
To evaluate the effects of amisulpride compared with other atypical antipsychotics for people with schizophrenia and schizophrenia‐like psychoses.
Search methods
We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CINAHL, EMBASE, MEDLINE and PsycINFO.
We updated this search in July 2012 and added 47 new trials to the awaiting classification section.
Selection criteria
We included randomised, at least single‐blind, trials comparing oral amisulpride with oral forms of aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia‐like psychoses.
Data collection and analysis
We extracted data independently. For continuous data we calculated weighted mean differences (MD), for dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention‐to‐treat basis based on a random effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate.
Main results
The review currently includes ten short to medium term trials with 1549 participants on three comparisons: amisulpride versus olanzapine, risperidone and ziprasidone. The overall attrition rate was considerable (34.7%) with no significant difference between groups. Amisulpride was similarly effective as olanzapine and risperidone and more effective than ziprasidone (leaving the study early due to inefficacy: n=123, 1 RCT, RR 0.21 CI 0.05 to 0.94, NNT 8 CI 5 to 50). Amisulpride induced less weight gain than risperidone (n=585, 3 RCTs, MD ‐0.99 CI ‐1.61 to ‐0.37) or olanzapine (n=671, 3 RCTs, MD ‐2.11 CI ‐2.94 to ‐1.29). Olanzapine was also associated with a higher increase of glucose (n=406, 2 RCTs, MD ‐7.30 CI ‐7.62 to ‐6.99). There was no difference in terms of cardiac effects and extra pyramidal symptoms (EPS) compared with olanzapine (akathisia: n= 587, 2 RCTs, RR 0.66 CI 0.36 to 1.21), compared with risperidone (akathisia: n=586, 3 RCTs, RR 0.80 CI 0.58 to 1.11) and compared with ziprasidone (akathisia: n=123, 1 RCT, RR 0.63, CI 0.11 to 3.67).
Authors' conclusions
There is little randomised evidence comparing amisulpride with other second generation antipsychotic drugs. We could only find trials comparing amisulpride with olanzapine, risperidone and ziprasidone. We found amisulpride may be somewhat more effective than ziprasidone, and more tolerable in terms of weight gain and other associated problems than olanzapine and risperidone. These data, however, are based on only ten short to medium term studies and therefore too limited to allow for firm conclusions.
Note: the 47 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.</description><subject>Amisulpiride</subject><subject>Amisulpride</subject><subject>Antipsychotic Agents</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotic medication: atypical</subject><subject>Anti‐psychotics</subject><subject>Benzodiazepines</subject><subject>Benzodiazepines - adverse effects</subject><subject>Benzodiazepines - therapeutic use</subject><subject>Clinical care ‐ by treatment category</subject><subject>Drugs</subject><subject>Humans</subject><subject>Medicine General & Introductory Medical Sciences</subject><subject>Mental health</subject><subject>Olanzapine</subject><subject>Piperazines</subject><subject>Piperazines - adverse effects</subject><subject>Piperazines - therapeutic use</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Risperidone</subject><subject>Risperidone - adverse effects</subject><subject>Risperidone - therapeutic use</subject><subject>Schizophrenia</subject><subject>Schizophrenia & psychosis</subject><subject>Schizophrenia - drug therapy</subject><subject>Sulpiride</subject><subject>Sulpiride - adverse effects</subject><subject>Sulpiride - analogs & derivatives</subject><subject>Sulpiride - therapeutic use</subject><subject>Thiazoles</subject><subject>Thiazoles - adverse effects</subject><subject>Thiazoles - therapeutic use</subject><issn>1465-1858</issn><issn>1469-493X</issn><issn>1465-1858</issn><issn>1469-493X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>RWY</sourceid><sourceid>EIF</sourceid><recordid>eNqFkMtOwzAURC0EoqXwC1V2rFL8TrJBastTqsQG1pbjOMQojYOdFIWvJ1EfKmxY2daM59w7AEwRnCEI8Q2inKGYxbPlHYScYzqr2xSfgPEghINyenQfgQvvPyAkPMHRORhhCBPEkmQMFvO18W1ZO5PpYKOdb31gm0K7QDZdbZQsA1k1pvadKmxjlA9y6wKvCvNt68LpyshLcJbL0uur3TkBbw_3r8uncPXy-Lycr0LFMMMhT3WkEogTGXOIiFYkklwShiIqadI_cJ4jjWXKtMQZySFCXNJckTTKIsYRmYDbbW6_6VpnSleNk6XoR19L1wkrjfitVKYQ73YjKOKUctwHXO8CnP1stW9Ev7vSZSkrbVsvIkI4QjGPeiffOpWz3judHygIiqF_se9f7Psf2ANiejzj4du-8N6w2Bq-TKk7oawqXI__J_cP5Qcz1pfL</recordid><startdate>20100120</startdate><enddate>20100120</enddate><creator>Komossa, Katja</creator><creator>Rummel‐Kluge, Christine</creator><creator>Hunger, Heike</creator><creator>Schmid, Franziska</creator><creator>Schwarz, Sandra</creator><creator>Silveira da Mota Neto, Joaquim I</creator><creator>Kissling, Werner</creator><creator>Leucht, Stefan</creator><creator>Komossa, Katja</creator><general>John Wiley & Sons, Ltd</general><scope>7PX</scope><scope>RWY</scope><scope>ZYTZH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20100120</creationdate><title>Amisulpride versus other atypical antipsychotics for schizophrenia</title><author>Komossa, Katja ; Rummel‐Kluge, Christine ; Hunger, Heike ; Schmid, Franziska ; Schwarz, Sandra ; Silveira da Mota Neto, Joaquim I ; Kissling, Werner ; Leucht, Stefan ; Komossa, Katja</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5252-6be7c9029a86013ec37a6a35174a4937a2ff1e2ab5ea2d3f0116a4fc3b7d75613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Amisulpiride</topic><topic>Amisulpride</topic><topic>Antipsychotic Agents</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotic medication: atypical</topic><topic>Anti‐psychotics</topic><topic>Benzodiazepines</topic><topic>Benzodiazepines - adverse effects</topic><topic>Benzodiazepines - therapeutic use</topic><topic>Clinical care ‐ by treatment category</topic><topic>Drugs</topic><topic>Humans</topic><topic>Medicine General & Introductory Medical Sciences</topic><topic>Mental health</topic><topic>Olanzapine</topic><topic>Piperazines</topic><topic>Piperazines - adverse effects</topic><topic>Piperazines - therapeutic use</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Risperidone</topic><topic>Risperidone - adverse effects</topic><topic>Risperidone - therapeutic use</topic><topic>Schizophrenia</topic><topic>Schizophrenia & psychosis</topic><topic>Schizophrenia - drug therapy</topic><topic>Sulpiride</topic><topic>Sulpiride - adverse effects</topic><topic>Sulpiride - analogs & derivatives</topic><topic>Sulpiride - therapeutic use</topic><topic>Thiazoles</topic><topic>Thiazoles - adverse effects</topic><topic>Thiazoles - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Komossa, Katja</creatorcontrib><creatorcontrib>Rummel‐Kluge, Christine</creatorcontrib><creatorcontrib>Hunger, Heike</creatorcontrib><creatorcontrib>Schmid, Franziska</creatorcontrib><creatorcontrib>Schwarz, Sandra</creatorcontrib><creatorcontrib>Silveira da Mota Neto, Joaquim I</creatorcontrib><creatorcontrib>Kissling, Werner</creatorcontrib><creatorcontrib>Leucht, Stefan</creatorcontrib><creatorcontrib>Komossa, Katja</creatorcontrib><collection>Wiley-Blackwell Cochrane Library</collection><collection>Cochrane Library</collection><collection>Cochrane Library (Open Aceess)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cochrane database of systematic reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Komossa, Katja</au><au>Rummel‐Kluge, Christine</au><au>Hunger, Heike</au><au>Schmid, Franziska</au><au>Schwarz, Sandra</au><au>Silveira da Mota Neto, Joaquim I</au><au>Kissling, Werner</au><au>Leucht, Stefan</au><au>Komossa, Katja</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Amisulpride versus other atypical antipsychotics for schizophrenia</atitle><jtitle>Cochrane database of systematic reviews</jtitle><addtitle>Cochrane Database Syst Rev</addtitle><date>2010-01-20</date><risdate>2010</risdate><volume>2013</volume><issue>2</issue><spage>CD006624</spage><epage>CD006624</epage><pages>CD006624-CD006624</pages><issn>1465-1858</issn><issn>1469-493X</issn><eissn>1465-1858</eissn><eissn>1469-493X</eissn><abstract>Background
In many countries of the industrialised world second generation (atypical) antipsychotics have become first line drug treatments for people with schizophrenia. The question as to whether, and if so how much, the effects of the various second generation antipsychotics differ is a matter of debate. In this review we examine how the efficacy and tolerability of amisulpride differs from that of other second generation antipsychotics.
Objectives
To evaluate the effects of amisulpride compared with other atypical antipsychotics for people with schizophrenia and schizophrenia‐like psychoses.
Search methods
We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CINAHL, EMBASE, MEDLINE and PsycINFO.
We updated this search in July 2012 and added 47 new trials to the awaiting classification section.
Selection criteria
We included randomised, at least single‐blind, trials comparing oral amisulpride with oral forms of aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia‐like psychoses.
Data collection and analysis
We extracted data independently. For continuous data we calculated weighted mean differences (MD), for dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention‐to‐treat basis based on a random effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate.
Main results
The review currently includes ten short to medium term trials with 1549 participants on three comparisons: amisulpride versus olanzapine, risperidone and ziprasidone. The overall attrition rate was considerable (34.7%) with no significant difference between groups. Amisulpride was similarly effective as olanzapine and risperidone and more effective than ziprasidone (leaving the study early due to inefficacy: n=123, 1 RCT, RR 0.21 CI 0.05 to 0.94, NNT 8 CI 5 to 50). Amisulpride induced less weight gain than risperidone (n=585, 3 RCTs, MD ‐0.99 CI ‐1.61 to ‐0.37) or olanzapine (n=671, 3 RCTs, MD ‐2.11 CI ‐2.94 to ‐1.29). Olanzapine was also associated with a higher increase of glucose (n=406, 2 RCTs, MD ‐7.30 CI ‐7.62 to ‐6.99). There was no difference in terms of cardiac effects and extra pyramidal symptoms (EPS) compared with olanzapine (akathisia: n= 587, 2 RCTs, RR 0.66 CI 0.36 to 1.21), compared with risperidone (akathisia: n=586, 3 RCTs, RR 0.80 CI 0.58 to 1.11) and compared with ziprasidone (akathisia: n=123, 1 RCT, RR 0.63, CI 0.11 to 3.67).
Authors' conclusions
There is little randomised evidence comparing amisulpride with other second generation antipsychotic drugs. We could only find trials comparing amisulpride with olanzapine, risperidone and ziprasidone. We found amisulpride may be somewhat more effective than ziprasidone, and more tolerable in terms of weight gain and other associated problems than olanzapine and risperidone. These data, however, are based on only ten short to medium term studies and therefore too limited to allow for firm conclusions.
Note: the 47 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>20091599</pmid><doi>10.1002/14651858.CD006624.pub2</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1465-1858 |
| ispartof | Cochrane database of systematic reviews, 2010-01, Vol.2013 (2), p.CD006624-CD006624 |
| issn | 1465-1858 1469-493X 1465-1858 1469-493X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4164462 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Amisulpiride Amisulpride Antipsychotic Agents Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use Antipsychotic medication: atypical Anti‐psychotics Benzodiazepines Benzodiazepines - adverse effects Benzodiazepines - therapeutic use Clinical care ‐ by treatment category Drugs Humans Medicine General & Introductory Medical Sciences Mental health Olanzapine Piperazines Piperazines - adverse effects Piperazines - therapeutic use Randomized Controlled Trials as Topic Risperidone Risperidone - adverse effects Risperidone - therapeutic use Schizophrenia Schizophrenia & psychosis Schizophrenia - drug therapy Sulpiride Sulpiride - adverse effects Sulpiride - analogs & derivatives Sulpiride - therapeutic use Thiazoles Thiazoles - adverse effects Thiazoles - therapeutic use |
| title | Amisulpride versus other atypical antipsychotics for schizophrenia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T22%3A26%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Amisulpride%20versus%20other%20atypical%20antipsychotics%20for%20schizophrenia&rft.jtitle=Cochrane%20database%20of%20systematic%20reviews&rft.au=Komossa,%20Katja&rft.date=2010-01-20&rft.volume=2013&rft.issue=2&rft.spage=CD006624&rft.epage=CD006624&rft.pages=CD006624-CD006624&rft.issn=1465-1858&rft.eissn=1465-1858&rft_id=info:doi/10.1002/14651858.CD006624.pub2&rft_dat=%3Cproquest_pubme%3E733611867%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733611867&rft_id=info:pmid/20091599&rfr_iscdi=true |